Please login to the form below

Not currently logged in

Covance to collaborate with Indiana University on trials

Will work with the US university on pharma and biotech studies

Clinical research organisation (CRO) Covance is to work with the Indiana Clinical and Translational Sciences Institute (CTSI) on early-stage clinical trials for its pharma and biotech clients.

Part of Indiana University's School of Medicine, CTSI will collaborate with the CRO on first-in-man and phase I trials.

Covance said the agreement would provide a significant opportunity to bring more phase I clinical studies to Indiana, combining CTSI's capabilities in Indianapolis and those of its own Evansville clinical research unit.

Rob Aspbury, vice president and general manager, global clinical pharmacology services at Covance, said: “The alliance with the Indiana CTSI will help us provide biopharmaceutical clients with quicker access to patients in a hospital setting that supports specialised care and monitoring.

“With quicker access to patients, we can streamline the drug development process and bring important new medications to patients who need them.”

The Indiana CTSI is a state-wide collaboration of Indiana University, Purdue University and the University of Notre Dame that aims to help translate scientific discoveries into new patient treatments.

It will provide Covance with access to a 24-patient facility at IU Health University Hospital in Indianapolis and may expand operations into a recently renovated 50-patient facility in the same building.  

Anantha Shekhar, director of the Indiana CTSI, said: “Our mission is to accelerate the rate at which this research travels out of the lab and into the care of the patients who need it.  This alliance with Covance will greatly enhance our ability to accomplish this vital work.”

Article by
Dominic Tyer

16th September 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...